Dr. Keogh founded BluMaiden Biosciences with the vision to harness the power of AI to unlock the therapeutic potential of human-derived natural products – molecules shaped by nature and refined by evolution. Under his leadership, BluMaiden has developed into a next-generation, AI-driven drug discovery company pioneering a reverse translation approach that leverages real-world clinical insights to uncover biological mechanism and identify novel drug candidates inspired by nature.
As Chief Executive Officer and a member of the Board of Directors, Dr Keogh drives BluMaiden’s global growth and strategic direction. He is is deeply involved in commercial across the US and international markets, overseeing strategic partnerships, investor and shareholder relations, and operational excellence to advance the company’s mission of creating safer, more biocompatible medicines.
Since founding BluMaiden in 2020, Dr. Keogh has led its development into an AI-driven drug discovery company that employs a reverse translation approach – leveraging clinical insights to identify biological mechanisms and enable target and natural product-based drug candidate selection. He has been instrumental in building the company’s platform, recruiting key founders, board members, and a scientific advisory board, as well as assembling the core team.
Prior to founding BluMaiden, Dr. Keogh has built the company’s foundations – assembling its core scientific and leadership team, establishing strategic alliances, and shaping an innovative discovery platform that bridges AI, chemistry, and human biology. His work reflect a rare blend of scientific depth and entrepreneurial execution, uniting cutting-edge computational approaches with real-world translational insight.
Before BluMaiden, Dr. Keogh played an active role in the biotechnology ecosystem, serving as an Entrepreneur-in-Residence in venture capital and contributing to the creation and growth of spin-out and venture-created biotech companies. He is also an alumnus of Johnson & Johnson Innovation JLABS and continues to mentor early-stage founders and entrepreneurs, providing strategic guidance and serving on multiple scientific advisory boards.
Early in his academic career, Dr. Keogh collaborated with global pharmaceutical leaders, clinician scientists, and academic researchers to advance metabolite biology, (poly)microbial-host interactions, and microbial biofilm dynamics. His early research, – sponsored by Bristol Myers Squibb Ltd. – focused on developing molecular tools to enhance drug purification through novel glycoselective bioaffinity technologies, leading to a successful university spin-out.
Dr. Keogh remains deeply passionate about advancing the science and business of AI and microbiome-based medicine and empowering teams to deliver transformative outcomes for patients worldwide.